This is an interview with Kyle Cetrulo, Founder and CEO of AuxoCell Laboratories, a company specializing in solid tissue processing using its AC:Px System. In addition to heading Auxocell and being a thought-leader on perinatal stem cells, Kyle is an organizer for the upcoming 2nd Annual Perinatal Stem Cell Society Conference that will take place each March in Aspen, CO.
[Read more…]
Hematopoietic Stem Cells (HSCs)
Could NiCord® by Gamida Cell Introduce a Paradigm Shift to HSCT?
Gamida Cell is an Israeli company specializing in cellular and immune therapies for the treatment of cancer and orphan genetic diseases. The company is developing a diverse clinical pipeline based on its proprietary NAM technology platform. It lead program, NiCord®, is now in Phase 3 development for allogeneic bone marrow transplantation.
NiCord® was granted Breakthrough Therapy Designation by the FDA, as well orphan drug designation by the European Medicines Agency (EMA). [Read more…]
Cord Blood Processing Method PrepaCyte-CB Leads in Engraftment Time
The cord blood processing method PrepaCyte-CB has been shown to engraft more quickly during the vital stage of post-transplant recovery than any other processing method. At the 15th Annual International Cord Blood Symposium in San Diego, California, in June 2017, the St. Louis Cord Blood Bank presented the median time it took patients infused with cord blood using either its Hetastarch or PrepaCyte-CB processing method to reach an absolute neutrophil count (ANC) of 500.
PrepaCyte-CB was found to engraft a full four days more quickly than the Hetastarch processing method (16 days versus 20 days) and has shown to be just as safe to the patient.1 Combining this data with those of other public data sources, PrepaCyte-CB was found to engraft more quickly than any other processing method. [Read more…]
Top 5 Cord Blood Industry Influencers
Below are our awards for the top five cord blood industry influencers worldwide.
These individuals are all renowned industry experts, innovative thought leaders, and highly sought after speakers, advisors, and board members. Their opinions on cord blood banking topics can substantially alter public perception.
Congrats to those on this list!
5 Cord Blood Investors Impacting the Global Marketplace
Inspired by the acquisition of Cord Blood Registry by AMAG Pharmaceuticals for $700M in June of 2015, this post considers five cord blood investors that are impacting the global marketplace. It includes traditional investments, acquisitions, and contributions from wealthy founders. If you are operating within the cord blood industry, you need to know these market investors. [Read more…]
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- …
- 27
- Next Page »